Skip to main content

Advertisement

Table 3 Risk of death from colorectal cancer according to KRAS codons 12 and 13, and BRAF mutations

From: Sex differences in the prognostic significance of KRAS codons 12 and 13, and BRAF mutations in colorectal cancer: a cohort study

  Entire cohort   Women   Men  
HR (95% CI) n(events) HR (95% CI) n(events) HR (95% CI) n(events)
KRAS status (unadjusted)       
 Wild-type 1.00 334 (113) 1.00 177 (52) 1.00 157 (61)
 Codon 12-mutated 1.05 (0.76–1.45) 156 (54) 1.32 (0.85–2.05) 83 (32) 0.81 (0.50–1.32) 73 (22)
 Codon 13-mutated 1.94 (1.18–3.19) 34 (18) 2.58 (1.31–5.09) 18 (10) 1.42 (0.68–2.96) 16 (8)
KRAS status (adjusted)       
 Wild-type 1.00 273 (87) 1.00 146 (39) 1.00 127 (65)
 Codon 12-mutated 1.02 (0.69–1.51) 132 (44) 1.29 (0.75–2.22) 67 (24) 0.74 (0.42–1.30) 65 (20)
 Codon 13-mutated 1.37 (0.74–2.54) 28 (13) 1.83 (0.79–4.23) 15 (7) 0.87 (0.34–2.72) 13 (6)
BRAF status (unadjusted)       
 Wild-type 1.00 446 (154) 1.00 227 (75) 1.00 219 (79)
 Mutated 1.32 (0.90–1.94) 78 (32) 1.23 (0.74–2.04) 50 (19) 1.56 (0.87–2.81) 28 (13)
BRAF status (adjusted)       
 Wild-type 1.00 370 (122) 1.00 184 (56) 1.00 186 (66)
 Mutated 1.56 (0.87–2.79) 63 (22) 1.47 ( 0.65–3.33) 44 (14) 3.50 (1.41–8.70) 19 (8)
  1. Adjusted analysis included age (continuous), sex, T stage (I-II, III, IV), N stage (0, 1, 2), M stage (0, 1), differentiation grade (high-intermediate vs. low and vascular invasion (+/−/unknown)), KRAS mutation status (wild-type, codon 12 mutation, codon 13 mutation) and BRAF mutation status (wild-type, mutated). One case with mutual KRAS codons 12 and 13 mutation was excluded from the analyses related to KRAS mutational status.